Dermatomyositis Treatment Guidelines

Introduction to IVIG Therapy

The British Association of Dermatologists' guidelines suggest that IVIg could be considered as maintenance treatment in patients with refractory disease unresponsive to other adjuvant drugs, which applies to patients who have previously required IVIG rescue therapy 1
IVIG has strong evidence supporting its use in dermatomyositis, particularly for patients with refractory disease unresponsive to other adjuvant drugs, and for patients who have previously required rescue therapy 1

Standard IVIG dosing for dermatomyositis is typically 2g/kg divided over several days, with treatment given at monthly intervals 1
Treatment may need to be prolonged for continued effect, and the proposed regimen of IVIG monthly at 2g/kg divided over two days aligns with guideline recommendations 1

Potential adverse effects of IVIG include headache, aseptic meningitis, thromboembolic events, and anaphylaxis, particularly in patients with risk factors or IgA deficiency 1, 2
To mitigate risks, checking serum IgA levels before administration if not previously done is recommended 2
Monitoring for infusion reactions and using slower infusion rates to minimize thromboembolic risk is also advised 2

Patients who have previously required IVIG rescue treatment and responded to it may benefit from continued therapy, as it can help maintain remission while reducing steroid dependence 1
The patient's previous response to IVIG rescue treatment suggests likely benefit from continued therapy, and IVIG has a favorable safety profile compared to long-term immunosuppression 1